fda approved semaglutide weight loss A big win for Wegovy: drug first in history to gain approval for reducing heart risks U.S. FDA finds no evidence

What has caused the shortage

Plateaus and Long-Term Results Most patients experience periods where weight loss temporarily slows: Plateaus are normal and expected during any weight loss journey Adjustments to diet, exercise or medication dosage may help overcome plateaus Long-term studies show that continued use helps maintain weight loss Periodic reassessment helps identify when strategy changes might be beneficial Studies show that patients who remained on semaglutide for more than a year maintained most of their weight loss, while those who discontinued the medication typically regained some weight

In addition, severe gastrointestinal complaints such as vomiting or diarrhea can impair the safe absorption of hormonal contraceptives

Semaglutide was originally developed as a diabetes medication